NENatonalinsutute forHealth and Care ExcellenceNICE贝guidanceTrastuzumab deruxtecanfor treating HER2-positiveunresectable or metastaticbreast cancer after 1 ormore anti-HER2treatmentsTechnology appraisal guidancePublished:1 February 2023www.nice.org.uk/quidance/ta862NICE 2023.All rights reserved.Subject to Notice of rights(https://www.nice.org.uk/temms-and-conditions#notice-of-rights).